Sökning: WFRF:(Janson Eva T)
> (1992-1994) >
Octreotide and inte...
Octreotide and interferon alfa : a new combination for the treatment of malignant carcinoid tumours
-
- Tiensuu Janson, Eva (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi
-
- Ahlström, Håkan (författare)
- Uppsala universitet,Enheten för radiologi
-
Andersson, T (författare)
-
visa fler...
-
- Öberg, Kjell (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi
-
visa färre...
-
(creator_code:org_t)
- 1992
- 1992
- Engelska.
-
Ingår i: European Journal of Cancer. - 0959-8049 .- 1879-0852. ; 28A:10, s. 1647-1650
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- 24 patients with malignant carcinoid tumours received octreotide and interferon alfa (IFN-alpha). All the patients initially received octreotide 50-100 micrograms, twice daily. When progressive symptoms or increasing biochemical markers were observed, the daily dose was raised to a median 300 micrograms. If the initial dose proved ineffective or if no improvement was seen after escalation, IFN-alpha was added (median 9 MU subcutaneously per week). After the addition of IFN-alpha, 17 of the 22 patients (77%) with elevated urinary 5-hydroxyindoleacetic acid showed a significant (> 50%) reduction. Only 1 patient progressed and 4 had continuously stable biochemical disease. No significant reduction in tumour size was noted; in 5 patients, the tumour continued to grow despite decreasing hormone levels. 18 patients had carcinoid syndrome when IFN-alpha was added in 10 (56%) symptoms ameliorated. Thus, the addition of IFN-alpha is beneficial for patients with malignant carcinoid tumours that progress and/or who do not respond to octreotide.
Nyckelord
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
- Female
- Humans
- Hydroxyindoleacetic Acid/urine
- Interferon-alpha/therapeutic use
- Male
- Malignant Carcinoid Syndrome/mortality/*therapy/urine
- Middle Aged
- Octreotide/therapeutic use
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas